Navigation Links
Sentara begins international trial -- open at only 24 US locations
Date:9/25/2008

Norfolk, VA September 23, 2008 Researchers at Sentara Cardiovascular Research Institute begin a new international study to explore the safety and effectiveness of stents to open airways of patients with advanced emphysema or Chronic Obstructive Pulmonary Disease (COPD).

The EASE (Exhale Airway Stents for Emphysema) Trial focuses on airway bypass, an investigational technique without surgery to create new pathways to release trapped air from within diseased lung tissue, thereby helping patients with advanced widespread emphysema breathe easier.

Similar to the stents used to prop open clogged arteries in heart patients, these drug-eluting stents are now holding open new passageways in the lungs.

Pulmonologists and cardiothoracic surgeons at Sentara Thoracic Surgery Center in Norfolk, Virginia are collaborating to perform this investigational procedure of the first wave of Virginia participants. During the procedure, a tube is guided through the mouth of trial participants to access the lung and implant up to six stents smaller than a pencil eraser. The goal is to relieve breathlessness and over inflated lungs hallmarks of this incurable, progressive disease.

Traditional treatment options for patients with severe emphysema are limited to lung reduction surgery, lung transplant, and inhalers, which have diminishing impact as the disease progresses. Airway bypass, done without open surgery, is considered minimally invasive and hoped to be an option for broader numbers of patients.

"Emphysema is really life limiting. Some of my patients who golfed a year ago now get winded taking a shower," says cardiothoracic surgeon Joseph Newton, Sentara Cardiovascular Research Institute's principal investigator for this trial. "Through research like this, I'm hopeful we are going to find a way to help these patients do things most of us take for granted," he continues.

That's just what trial candidate John Woodard is hoping for. The 61-year-old Suffolk resident is being evaluated Tuesday, September 22 at Sentara to begin the enrollment process.

"I don't look sick," says Woodard. "You wouldn't know any better until you saw me exercise," continues Woodard who ran 35 miles each week up until about 10 years ago. Woodard retired a year ago because of his condition. "I still play golf, but I have to bring my oxygen with me," he says.

"Research like this gives new hope of a longer-term solution for more people. Transplant is not a practical option for a lot of people with severe emphysema," says Dr. Carolyn Fruci, pulmonologist and critical care specialist involved in the study. "What's exciting is the possibility of patients regaining some of the everyday freedoms lost to this disease," Fruci continues.

Transplant, one of the only treatments today for patients with severe emphysema, is not plausible for every patient. Participation in this trial does not prevent patients from being considered for lung transplantation at a later time.

For Woodard, who has been coping with COPD for the last 10 years, participating in this research offers hope. "I'm up for most anything. Naturally if there's any benefitto me or anybody elsethat would be wonderful," say Woodard, who is being evaluated for participation in the trial.


'/>"/>

Contact: Cheri Hinshelwood
CSHINSHE@sentara.com
757-594-1036
Broncus Technologies
Source:Eurekalert  

Related biology news :

1. Building a stronger roof over your head: 3 little pigs project begins first tests
2. 8-day undersea mission begins experiment to improve coral reef restoration
3. War between the sexes begins before twins birth, TAU researchers say
4. iPlant Kickoff Conference at CSHL begins tackling plant biologys grand challenges
5. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
6. DHS Begins Collecting 10 Fingerprints From International Visitors at New Yorks John F. Kennedy International Airport
7. DHS Begins Collecting 10 Fingerprints From International Visitors at Detroit Metropolitan Wayne County Airport
8. DHS Begins Collecting 10 Fingerprints From International Visitors at Orlando International Airport
9. DHS Begins Collecting 10 Fingerprints From International Visitors at Miami International Airport
10. DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport
11. DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sentara begins international trial -- open at only 24 US locations
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a ... lab samples to full-size tissues, bones, even whole organs to implant in people ... delivers blood deep into the developing tissue. , Current bioengineering techniques, including ...
Breaking Biology Technology: